10mM in DMSO for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Protected from light,Store at -80°C Ships Dry ice packs + Cold packs Check lot-specific COA for exact specifications.
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Cited in 19 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
Cy5.5 is a CY dye. CY, short for Cyanine, is a compound consisting of two nitrogen atoms connected by an odd number of methyl units. Cyanine compounds have the characteristics of long wavelength, adjustable absorption and emission, high extinction coefficient, good water solubility and relatively simple synthesis. CY dyes are of en used for the labeling of proteins, antibodies and small molecular compounds. For the labeling of protein antibodies, the combination can be completed through a simple mixing reaction. Below, we introduce the labeling method of protein antibody labeling, which has certain reference significance . Storage: protect from light.
In Vitro
Protocol 1.Protein Preparetion 1) In order to obtain the best labeling effect, please prepare the protein (antibody) concentration as 2 mg/mL. 2) The pH value of protein solution shall be 8.5±0.5. If the pH is lower than 8.0, 1 M sodium bicarbonate shall be used for adjustment. 3) If the protein concentration is lower than 2 mg/mL, the labeling efficiency will be greatly reduced. In order to obtain the best labeling efficiency, it is recommended that the final protein concentration range is 2-10 mg/mL. 4) The protein must be in the buffer without primary amine (such as Tris or glycine) and ammonium ion, otherwise the labeling efficiency will be affected. 2.Dye Preparation (Cy5.5) Add anhydrous DMSO into the vial of Cy5.5 to make a 10 mM stock solution. Mix well by pipetting or vortex. 3.Calculation of dye dosage The amount of Cy5.5 required for reaction depends on the amount of protein to be labeled, and the optimal molar ratio of Cy5.5 to protein is about 10. Example: assuming the required marker protein is 500 μL 2 mg/mL IgG (MW=150,000), use 100 μL DMSO dissolve 1 mg Cy5.5, the required Cy5.5 volume is 5.05 μL, and the detailed calculation process is as follows: 1) mmol (IgG) = mg/mL (IgG) ×mL (IgG) / MW (IgG) =2 mg/mL × 0.5 mL / 150,000 mg/mmol= 6.7×10-6 mmol 2) mmol (Cy5.5) = mmol (IgG) × 10 = 6.7×10-6 mmol×10 = 6.7 × 10-5 mmol 3) μL (Cy5.5) = mmol (Cy5.5) ×MW (Cy5.5) / mg/μL (Cy5.5) = 6.7 ×10-5 mmol ×753.88 mg/mmol / 0.01 mg/μL = 5.05 μL (Cy5.5) 4.Run conjugation reaction 1) A good volume of freshly prepared 10 mg/mL Cy5.5 is slowly added to 0.5 mL protein sample In solution, gently shake to mix, then centrifuge briefly to collect the sample at the bottom of the reaction tube. Don'tmix well to prevent protein samples from denaturation and inactivation. 2) The reaction tubules were placed in a dark place and incubated gently at room temperature for 60 minutes at intervals.For 10-15 minutes, gently reverse the reaction tubules several times to fully mix the two reactants and raise the bar efficiency. 5.Purify the conjugation The following protocol is an example of dye-protein conjugate purification by using a SepHadex G-25 column. 1) Prepare SepHadex G-25 column according to the manufacture instruction. 2) Load the reaction mixture (From \Run conjugation reaction\) to the top of the SepHadex G-25 column. 3) Add PBS (pH 7.2-7.4) as soon as the sample runs just below the top resin surface. 4) Add more PBS (pH 7.2-7.4) to the desired sample to complete the column purification. Combine the fractions that contain the desired dye-protein conjugate. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Cy5.5-labeled factor VIIa is developed for imagining cancer. Cy5.5 labeled with these targeting proteins specifically localize to the tumor xenografts for at least 14 days but unconjugated Cy5.5 does not localize to any xenografts or organs. This method of imaging anti-tissue factor in the tumor VECs may be useful in detecting primary tumors and metastases as well as monitoring in vivo therapeutic responses . pH/temperature sensitive magnetic nanogels conjugated with Cy5.5-labled lactoferrin (Cy5.5-Lf-MPNA nanogels) are developed as a promising contrast agent for preoperative MRI and intraoperative fluorescence imaging of glioma. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| PubChem CID | 131875897 |
|---|---|
| MeSH Entry Terms | CY5.5;CY5.5 cyanine dye |
| Molecular Weight | 917.05 |
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →Full quality attributes and acceptance criteria for this grade.
View spec sheet →| 1. Xianyang Li, Jingyuan Huang, Xin Wu, Xianling Piao, Danning Lv, Gude Zhang, Dong June Ahn, Chunzhi Cui. (2023) Obviously Enhanced Fluorescent Signal of Core-Shell Nanostructures through Simultaneous Regulation of Spectral Overlap and Shell Thickness for Imaging and Photothermal Therapy of Ovarian Cancer Cells. PARTICLE & PARTICLE SYSTEMS CHARACTERIZATION, [PMID:] [10.1002/ppsc.202300083] |
| 2. Meng Xu, Haidong Zha, Jiamao Chen, Simon Ming-Yuen Lee, Qi Wang, Ruibing Wang, Ying Zheng. (2023) “Ice & Fire” Supramolecular Cell-Conjugation Drug Delivery Platform for Deep Tumor Ablation and Boosted Anti-Tumor Immunity. ADVANCED MATERIALS, [PMID:37547984] [10.1002/adma.202305287] |
| 3. Mingqiao Li, Hedan Xu, Nan Zhao, Liangjun Zhang, Haihan Xia, Xiaoxun Zhang, Qiao Li, Min Liao, Qiong Pan, Zeng Yi, Jin Chai. (2023) Hepatocyte-targeted hyaluronic acid-polyethyleneimine conjugates for acute liver injury therapy by ROS elimination and inflammation modulation. MATERIALS & DESIGN, [PMID:] [10.1016/j.matdes.2023.112212] |
| 4. Xuzi Cai, Si Shi, Gui Chen, Min Zhong, Yuanyuan Yang, Ziyi Mai, Yang Tian, Jinxiu Tan, Lijuan He, Chunhui Cui, Zhiqiang Yu, Xuefeng Wang. (2022) Glutamine metabolism targeting liposomes for synergistic chemosensitization and starvation therapy in ovarian cancer. Acta Biomaterialia, [PMID:36596434] [10.1016/j.actbio.2022.12.052] |
| 5. Meiting Li, Yaqian Zhang, Xiaoge Zhang, Zhuoyin Liu, Junjie Tang, Miao Feng, Baizhu Chen, Dalin Wu, Jie Liu. (2022) Degradable Multifunctional Porphyrin-Based Porous Organic Polymer Nanosonosensitizer for Tumor-Specific Sonodynamic, Chemo- and Immunotherapy. ACS Applied Materials & Interfaces, [PMID:36281484] [10.1021/acsami.2c14776] |
| 6. Cai Xuzi, Wang Kang-Nan, Ma Wen, Yang Yuanyuan, Chen Gui, Fu Huijiao, Cui Chunhui, Yu Zhiqiang, Wang Xuefeng. (2021) Multifunctional AIE iridium (III) photosensitizer nanoparticles for two-photon-activated imaging and mitochondria targeting photodynamic therapy. JOURNAL OF NANOBIOTECHNOLOGY, 19 (1): (1-13). [PMID:34425820] [10.1186/s12951-021-01001-4] |
| 7. Ying Chen, Zi-Hao Li, Pei Pan, Run-Yao Zeng, Xian-Zheng Zhang. (2021) Tumor-Specific ONOO– Nanogenerator for Improved Drug Delivery and Enhanced Chemotherapy of Tumor. ACS Nano, [PMID:34275285] [10.1021/acsnano.1c01312] |
| 8. Wang Haijun, Jia Dianlong, Yuan Dandan, Yin Xiaolei, Yuan Fengjiao, Wang Feifei, Shi Wenna, Li Hui, Zhu Li-Min, Fan Qing. (2021) Dimeric Her2-specific affibody mediated cisplatin-loaded nanoparticles for tumor enhanced chemo-radiotherapy. JOURNAL OF NANOBIOTECHNOLOGY, 19 (1): (1-23). [PMID:33985511] [10.1186/s12951-021-00885-6] |
| 9. Han Wu, Hao Xing, Meng-Chao Wu, Feng Shen, Yu Chen, Tian Yang. (2021) Extracellular-vesicles delivered tumor-specific sequential nanocatalysts can be used for MRI-informed nanocatalytic Therapy of hepatocellular carcinoma. Theranostics, [PMID:33391461] [10.7150/thno.46124] |
| 10. Hafza Behroz Mehvish, Shirong Zhang, Yi Liang, Da Sun, Xu Qiu, Kai Qu, Xian Qin, Jiawei Li, Fei Yan, Chunhui Lang, Lixin Xu, Guixue Wang, Jian Chen, Bo He, Kun Zhang, Wei Wu. (2025) Enhanced Osteoporosis Treatment via Nano Drug Coating Encapsulating Lactobacillus rhamnosus GG. ACS Applied Materials & Interfaces, [PMID:39789866] [10.1021/acsami.4c17985] |
| 11. Yunhao Wang, Lei Ding, Ziguo Lin, Baolong Li, Di Hu, Shichen Zhang, Shujun Zhou, Yuxiang Ning, Fei Xin, Yunfei Ying, Fukai Zhu, Peiyuan Wang, Yanfeng Wang. (2025) Mesoporous dual-atom nanozyme induced cuproptosis and apoptosis for boosting immunogenic cell death along with reprogramming tumor immune-suppressive microenvironment. CHEMICAL ENGINEERING JOURNAL, [PMID:] [10.1016/j.cej.2025.160294] |
| 12. Ting Wang, Jie Chen, Chuandong Shu, Xinkun Shen, Yuanyuan Fu, Menghuan Li, Zhong Luo. (2025) Orally-administrable supramolecular probiotic capsules enable cooperative colon-targeted inflammation inhibition for ameliorating ulcerative colitis. Acta Biomaterialia, [PMID:39884521] [10.1016/j.actbio.2025.01.049] |
| 13. Huijiao Fu, Xiaoqiao Guo, Feng Fang, Cao Zhou, Yuanyuan Chen, Xuanbo Zhang, Bingchen Zhang, Xinran Li, Qiwen Liu, Jie Liu, Wei Chen, Ling Yu, Zhiqiang Yu, Xuefeng Wang. (2025) STING pathway activation with cisplatin polyprodrug nanoparticles for chemo-immunotherapy in ovarian cancer. JOURNAL OF CONTROLLED RELEASE, [PMID:39993638] [10.1016/j.jconrel.2025.02.061] |
| 14. Zhenzhen Feng, Gui Chen, Min Zhong, Ling Lin, Ziyi Mai, Yan Tang, Guimei Chen, Wen Ma, Guang Li, Yuanyuan Yang, Zhiqiang Yu, Meng Yu. (2023) An acid-responsive MOF nanomedicine for augmented anti-tumor immunotherapy via a metal ion interference-mediated pyroptotic pathway. BIOMATERIALS, [PMID:37738743] [10.1016/j.biomaterials.2023.122333] |
| 15. Wang Haoyu, Li Lei, Cao Xinran, Zhen Mingming, Wang Chunru, Bai Chunli. (2023) Application of mannose-modified fullerene immunomodulator selectively polarizes tumor-associated macrophages potentiating antitumor immunity. Nano Research, 16 (11): (12855-12863). [PMID:] [10.1007/s12274-023-6266-x] |
| 16. Zihao Wang, Ziming Jiang, Yu Zhang, Congwei Wang, Zhaoyang Liu, Zhankui Jia, Sudhanshu Bhushan, Jinjian Yang, Zhengguo Zhang. (2024) Exosomes derived from bladder epithelial cells infected with uropathogenic Escherichia coli increase the severity of urinary tract infections (UTIs) by impairing macrophage function. PLoS Pathogens, 20 (1): (e1011926). [PMID:38190378] [10.1371/journal.ppat.1011926] |
| 17. Yaoyu Hu, Pengfei Zhu, Junwei Deng, Yi Yu, Qian Chen, Haitao Wu, Zhengbao Zha, Hua Wang, Yan Ma. (2025) Hydrogen Therapy and Lipopolysaccharide Trapping with MgB2@Inulin Gel for Reversing Colitis and Its Associated Psychiatric Complications via the Gut–Brain Axis. ACS Nano, [PMID:40700348] [10.1021/acsnano.5c03843] |
| 18. Yin Xiujuan, Xue Shuqin, Ji Jiaqi, Zhao Mingyu, Shao Min, Yin Likang, Zhang Saisai, Liu Lei, Li Bin, Zhang Lei, Li Yuan, Wang Xiao. (2025) Ultrasound-activated dual-nanozyme platform for targeted ROS scavenging and NO delivery in liver fibrosis therapy. Advanced Composites and Hybrid Materials, 8 (4): (1-23). [PMID:] [10.1007/s42114-025-01411-0] |
| 19. Arbab Ali, Mengjie Wang, Haoxiang Guo, Chao Jiang, Ze Wang, Xin Dai, Yunfeng Zong, Yuan Liu. (2025) Triglyceride-Rich Conditions Reshape the Protein Corona and Alter Nanobio Interactions. ACS Applied Materials & Interfaces, [PMID:40968085] [10.1021/acsami.5c15105] |
